ArticleJournal of pharmacy & bioallied sciences2025
Investigating the Impact of COVID-19 on Laboratory Parameters in Diabetic Retinopathy of the Central Rural Population of India.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 has significantly impacted the healthcare system globally and posed high effects on subjects with chronic diseases such as diabetes and sequel like diabetes retinopathy. Aim: To assess the impact of COVID-19 on laboratory parameters in diabetic retinopathy in the central rural population of India. Materials and Methods: The study assessed 100 subjects with diabetic retinopathy who underwent COVID-19 vaccination. In all the subjects, blood glucose, glycosylated haemoglobin, urea, creatinine, total bilirubin, total protein, albumin, SGOT, SGPT/ALT, ALP, and cholesterol levels were assessed to assess any association with DR progression. For quality control, validation of calibration Multical-XL and control Erba Path and Erba Norm results was done before processing the sample. In laboratory parameters, blood glucose was assessed using glucose oxidase peroxidase (GOD) method, glycosylated hemoglobin with immunoturbidimetrique method, Urea by urease) enzymatic method, creatinine using enzymatic method, total bilirubin by Diazo method, total protein using Biuret method, albumin by BCG method, SGOT/AST - IFCC without the pyridoxal phosphate method, SGPT/ALT with IFCC without the pyridoxal phosphate method, ALP by AMP method, and cholesterol by CHOD-POD method. The data gathered were statistically analyzed using SPSS (software version 24.0) for assessment of descriptive measures, Student t-test, and ANOVA [P < 0.05]. Results: It was seen that in individuals with <5 years of diabetes, 34% had mild NPDR, 5% had moderate NPDR, 3% had severe NPDR, and 5% had PDR. Studies show that the 6-10-year period NPDR was more accounting, and as the duration of diabetes progressed, PDR was on the rise, reaching a peak of 11-15 years. We observed a significant change between and within groups. Conclusion: The present study concludes that hypoglycemia increases renal impairment and diabetic retinopathy incidence. However, its incidence has remarkably increased, with diabetes duration and diabetic age being reduced significantly after COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.